Recruiting Studies
Baxduo-PACIFIC: A Phase III Renal Outcomes and Cardiovascular Mortality Study to Investigate the Efficacy and Safety of Baxdrostat in Combination With Dapagliflozin in Participants With Chronic Kidney Disease and High Blood Pressure (BaxDuo-Pacific)
Investigational product: Baxdrostat
Population:
eGFR ≥30 and <60 mL/min/1.73 m2 with UACR between 3.39 mg/mmol and 56.5 mg/mmol, or
eGFR ≥30 and ≤75 mL/min/1.73 m2 with UACR between 56.5 mg/mmol and ≤565 mg/mmol or UPCR between 79 mg/mmol and 790 mg/mmol
Phase: III
Starting year: 2025
National lead: prof.dr. M.H. de Borst (UMCG)
PROMISE: Potassium correction for RAAS optimization in chronic kidney disease
Investigational product: Patiromer
Population: Stage 3b-4 CKD with ACR >3 mg/mmol
Phase: IV
Starting year: 2024
National lead: prof.dr. M.H. de Borst (UMCG)
Follow-up Studies
K+ in CKD trial
Investigational product: Potassium chloride / potassium citrate
Population: Stage 3b-4 CKD with ACR >3 mg/mmol
Phase: III
Starting year: 2017
National lead: prof.dr. E.J. Hoorn (Erasmus MC)
Contact NEFRO-NL
Nephrology Research Organization Netherlands (NEFRO-NL)
Would you like to know more about our foundation, or would you like to use our services? Please reach out to Sara at info@nefro-nl.nl and we will answer you as soon as possible.
Sara Roscioni, project manager